Business and Economy
GSK Acquires US Cancer Biotech Nuvalent for $10.6 Billion
GSK announces its largest-ever acquisition, buying US cancer biotech Nuvalent for $10.6 billion in a major oncology push under new CEO Luke Miels.
—4 min read
Tag
1 article
GSK announces its largest-ever acquisition, buying US cancer biotech Nuvalent for $10.6 billion in a major oncology push under new CEO Luke Miels.